This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights SAP, Abbott Laboratories, Citigroup, Team and Vaso
by Zacks Equity Research
SAP, Abbott Laboratories, Citigroup, Team and Vaso are part of the Zacks top Analyst Blog.
Align Technology (ALGN) Beats on Q2 Earnings, Lowers '24 Sales View
by Zacks Equity Research
Align Technology's (ALGN) records second-quarter 2024 revenue growth across all regions. This was mostly due to a robust performance by the Imaging Systems & CAD/CAM Services business segment.
Edwards Lifesciences (EW) Q2 Earnings Meet Mark, Margins Crash
by Zacks Equity Research
Edwards Lifesciences (EW) reports strong contributions from the TMTT product group in the second quarter of 2024.
Chemed (CHE) Q2 Earnings Miss Estimates, Margins Expand
by Zacks Equity Research
Chemed's (CHE) VITAS segment delivers impressive revenue growth and margin expansion in the second quarter of 2024.
Top Analyst Reports for SAP, Abbott Laboratories & Citigroup
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including SAP SE (SAP), Abbott Laboratories (ABT) and Citigroup Inc. (C), as well as two micro-cap stocks Team, Inc. (TISI) and Vaso Corporation (VASO).
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Quest Diagnostics (DGX) Tops Q2 Earnings, Raises 2024 Outlook
by Zacks Equity Research
Quest Diagnostics (DGX) delivers impressive base business growth in the second quarter of 2024.
Jobless Claims Increased More Than Expected
by Zacks Equity Research
Jobless Claims Increased More Than Expected
Abbott (ABT) Q2 Earnings Surpass Estimates, Margins Expand
by Zacks Equity Research
Abbott (ABT) delivers a strong underlying base business performance in the second quarter of 2024.
Jobless Claims Rise Again, D.R. Horton Posts Strong Quarter
by Mark Vickery
+1.867 million longer-term jobless claims is the highest single-week figure we've seen since November of 2021.
Compared to Estimates, Abbott (ABT) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Abbott (ABT) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Abbott (ABT) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 3.64% and 0.22%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Pre Q3 Earnings: Is Hologic (HOLX) Stock a Portfolio Must-Have?
by Moumi Mondal
Hologic (HOLX) benefits from its unique set of businesses, each underpinned by its durable growth drivers. The impressive YTD price rally, earnings prowess and attractive valuation make the stock a top investment pick.
Dow Closes at New High as Q2 Earnings Season Heats Up
by Mark Vickery
Earnings season only picks up steam in the weeks to come.
Here's How Abbott (ABT) is Placed Ahead of Q2 Earnings Release
by Zacks Equity Research
Abbott Laboratories' (ABT) second-quarter 2024 results are likely to reflect broad-based strength across several businesses and solid progress in the pipeline.
Wall Street Bulls Look Optimistic About Abbott (ABT): Should You Buy?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Abbott (ABT) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Abbott (ABT) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $101.64, marking a -0.47% move from the previous day.
Hims & Hers (HIMS) Gains 37.7% in Three Months: What's Next?
by Debanjana Dey
Hims & Hers (HIMS) is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.
DexCom (DXCM), Abbott to Launch First FDA Cleared OTC CGMs
by Zacks Equity Research
Dexcom (DXCM) and Abbott are set to launch their first FDA-approved over-the-counter CGMs, Stelo and Lingo & Libre Rio, respectively, in the United States this summer.
Medtronic Loses 5% in a Month: What's Next for MDT Investors?
by Urmimala Biswas
Medtronic's (MDT) stock suffers as a result of geopolitical complications and supply issues despite an expanding portfolio and strong strategic executions.
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
by Zacks Equity Research
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Abbott (ABT) Exceeds Market Returns: Some Facts to Consider
by Zacks Equity Research
In the closing of the recent trading day, Abbott (ABT) stood at $105.49, denoting a +0.18% change from the preceding trading day.
Abbott's (ABT) EPD Expansion Continues Despite FX Headwind
by Zacks Equity Research
Banking on the successful execution of its Branded Generic operating model, Abbott's (ABT) EPD is well-positioned for sustained growth in many of the growing pharmaceutical markets.
The Zacks Analyst Blog Highlights Abbott Laboratories, BP, Gilead Sciences, Smith-Midland and Crimson Wine
by Zacks Equity Research
Abbott Laboratories, BP, Gilead Sciences, Smith-Midland and Crimson Wine are included in this Analyst Blog.
Wall Street Analysts Think Abbott (ABT) Is a Good Investment: Is It?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Abbott (ABT) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?